5 results about "Induced platelet aggregation" patented technology

This invention relates to the fields of molecular biology and biomedicine, disclosing plasma-active peptides with antithrombotic effects and their uses. The invention obtains various active peptides from plasma through screening and solid-phase synthesis, and confirms their biological activity through in vitro platelet aggregation experiments and in vivo arterial thrombosis model experiments. Results show that peptides 1957, 1960, and 1961 significantly inhibit collagen-induced platelet aggregation, exhibiting good antiplatelet activity; animal experiments show that peptides 1955, 1957, 1960, and 1961 significantly inhibit arterial thrombosis. These active peptides are derived from endogenous plasma components, belonging to natural antithrombotic substances, possessing good physiological compatibility and safety advantages, and reducing the risk of immunogenicity and adverse reactions. These peptides can exert antithrombotic effects without relying on traditional antiplatelet drugs, providing a new source of active molecules and treatment options for the prevention and treatment of thrombotic diseases.

The invention provides an isoquinoline derivative with a novel structure, a pharmaceutically acceptable salt thereof, a preparation method of the isoquinoline derivative, a pharmaceutical composition containing the isoquinoline derivative and pharmaceutical application of the isoquinoline derivative, and belongs to the technical field of medicines. In-vitro experiments show that the isoquinoline derivative has significant inhibitory activity on arachidonic acid-induced platelet aggregation, and the antiplatelet activity of part of compounds is superior to that of aspirin. In a rat carotid artery thrombosis model induced by FeCl3, the isoquinoline derivative remarkably prolongs thrombosis time and reduces thrombus weight, and the in-vivo antithrombotic curative effect of the isoquinoline derivative is equivalent to that of aspirin and ticagrelor. A mouse tail bleeding model shows that the side effects of bleeding amount and bleeding time of the isoquinoline derivative are obviously lower than those of aspirin and ticagrelor. Therefore, the series of isoquinoline derivatives have the advantages of efficient antithrombotic effect and low bleeding risk, and have good application prospects in preparation of drugs for preventing and treating thrombotic diseases. In addition, the preparation method provided by the invention has the advantages of easily available raw materials, simple steps and strong operability, and the obtained target product has high quality and good efficiency.

The application discloses a cinnoline PAR4 antagonist and medical application thereof. The application relates to a compound of formula (I), stereoisomers, tautomers, pharmaceutically acceptable salts, esters, solvates or prodrugs thereof. The compound of the application can inhibit and prevent platelet aggregation induced by PAR4, can be used for treating and preventing thromboembolic diseases, and thus can be used as an anti-platelet drug.

This invention relates to an IRAK4 degrading agent and its uses. This degrading agent can be used to treat or prevent diseases such as cancer, neurodegenerative diseases, viral diseases, autoimmune diseases, inflammatory diseases, hereditary diseases, hormone-related diseases, metabolic diseases, organ transplant-related diseases, immunodeficiency diseases, destructive bone diseases, proliferative diseases, infectious diseases, cell death-related conditions, thrombin-induced platelet aggregation, liver diseases, pathological immune conditions involving T cell activation, cardiovascular diseases, or CNS diseases.

The application discloses a tetrazole derivative, which has a structure shown in a general formula I. The application also discloses a composition containing the tetrazole derivative and application of the tetrazole derivative in preparation of a drug for preventing and resisting stroke. The inventors of the application have confirmed through multiple experiments that the compound has obvious inhibiting effect on ADP-induced platelet aggregation activity, outstanding damage protection effect on OGD / R fetal rat primary cortical neuron cells and neuron-like cells induced and differentiated from neuroblastoma cells (N2A), good anti-stroke efficacy on an animal model of focal cerebral ischemia constructed by a line plug method for temporarily blocking a middle cerebral artery and good rat oral pharmacokinetic properties. Therefore, the compound can be applied to a drug for treating and preventing stroke as a neuroprotective agent.